The shares of the American pharmaceutical company Pfizer are falling 3.69% to $ 37.20 on the New York Stock Exchange, while those of the modern biotechnology company shoot 10.44% to $ 98.72, after the results of the vaccine Moderna versus Covid-19’s experimental results reveal a 94.5% efficacy rate – plus 4.5 percentage points – and demonstrate that it can be stored at normal refrigerator temperatures.
“It is higher than the 90% efficiency announced by the Pfizer / BioNTech vaccine that it announced last week. The vaccine developed by Moderna can also be stored for longer than one from Pfizer, facilitating logistics. The markets reacted well to the news and the refuge assets devalued it again, ”said XTB analysts in research.
According to JPMorgan analysts, Moderna’s vaccine logistics are less expensive, but the storage requirements for both drugs should converge.
Moderna’s third and final phase of clinical trials began in the United States in July and involves more than 30,000 participants. The American company will submit an application for emergency use authorization to the Food and Drug Administration (FDA) in the coming weeks. “This is a crucial moment in the development of our candidate vaccine against covid-19,” stated Moderna’s executive director, Stéphane Bancel.
Greater efficiency and better storage. What is known about the vaccine of Moderna
—
